High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Female
Gene Rearrangement
Genetic Predisposition to Disease
Humans
In Situ Hybridization, Fluorescence
Lymphoma, Large B-Cell, Diffuse
/ genetics
Male
Middle Aged
Phenotype
Predictive Value of Tests
Proto-Oncogene Proteins c-bcl-2
/ genetics
Proto-Oncogene Proteins c-bcl-6
/ genetics
Reproducibility of Results
BCL2 rearrangements
BCL6 rearrangements
Diffuse large B-cell lymphoma (DLBCL)
Fluorescence in situ hybridisation multiprobe BCL2/BCL6
MYC rearrangements
Multiplex fluorescence in situ hybridisation
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
02
11
2020
accepted:
14
03
2021
revised:
07
03
2021
pubmed:
27
3
2021
medline:
5
10
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Chromosomal rearrangements involving BCL2, BCL6 and MYC are commonly found in the most frequent B cell lymphomas, namely follicular lymphomas (FLs) and diffuse large B-cell lymphomas (DLBCLs). Particularly, BCL2-rearrangement represents a diagnostic hallmark in FLs, whereas MYC translocation can occur simultaneously with BCL2 and/or BCL6 rearrangements, defining a specific category of DLBCLs with a poorer prognosis. In this study, we aim to validate the diagnostic performance of multiplex BCL2/BCL6 FISH approach in formalin-fixed paraffin-embedded FLs and DBCLs and cytological samples of DLBCL comparing to the classic set of single break-apart probes. We collected a series of lymphomas, including 85 DLBCLs, 45 FLs and 36 other B-cell lymphoma histotypes and 16 cytological samples of DLBCLs. MYC, BCL2 and BCL6 rearrangements were previously assessed by a classic FISH test using single break-apart probes. All samples were analysed by a multiplex FISH assay. In the FL series, 38 cases showed BCL2-R; in the DLBCLs series, MYC-R was detected in 21 out of 85 DLBCL patients, BCL2-R in 10 out of 85 and BCL6-R in 33 out of 85. In the DLBCL cytological series, MYC-R was detected in 4 out of 16, BCL2-R in 4 out of 16 and BCL6-R in 1 out of 16. Notably, in FFPE, 13 double-hit lymphomas (DHLs) and 3 triple-hit lymphomas (THLs) were detected; in the cytological series, only 3 DHL cases were observed. The dual BCL2/BCL6 FISH probe test results were fully concordant with the results obtained using classic BCL2 and BCL6 single break apart. Particularly, multiplex FISH to simultaneously detect BCL2-R and BCL6-R on a single slide could find a wide application in the characterisation of double- and triple-hit DLBCLs.
Identifiants
pubmed: 33768318
doi: 10.1007/s00428-021-03084-8
pii: 10.1007/s00428-021-03084-8
pmc: PMC8448700
doi:
Substances chimiques
BCL2 protein, human
0
BCL6 protein, human
0
Biomarkers, Tumor
0
Proto-Oncogene Proteins c-bcl-2
0
Proto-Oncogene Proteins c-bcl-6
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-573Informations de copyright
© 2021. The Author(s).
Références
Pathology. 2020 Jan;52(1):68-77
pubmed: 31735344
Hemasphere. 2019 Jul 31;3(5):e284
pubmed: 31942539
Diagn Cytopathol. 2017 Nov;45(11):1005-1019
pubmed: 28594112
Hematol Oncol. 2019 Jun;37 Suppl 1:19-23
pubmed: 31187528
Blood. 2011 Feb 24;117(8):2319-31
pubmed: 21119107
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Mod Pathol. 2017 Dec;30(12):1688-1697
pubmed: 28776574
Am J Surg Pathol. 2015 Aug;39(8):1132-9
pubmed: 25828391
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Diagn Cytopathol. 2012 Jun;40(6):542-55
pubmed: 22619129
Anticancer Res. 2009 Nov;29(11):4649-55
pubmed: 20032416
J Clin Pathol. 2020 Feb;73(2):96-101
pubmed: 31562206
Virchows Arch. 2019 Oct;475(4):513-518
pubmed: 31388760
Cancer Cytopathol. 2011 Aug 25;119(4):254-62
pubmed: 21560251
Cancer Cytopathol. 2011 Aug 25;119(4):263-71
pubmed: 21560252
Cancer. 2016 Feb 15;122(4):559-64
pubmed: 26565895